| Literature DB >> 10448291 |
P J Woll1, I Judson, S M Lee, S Rodenhuis, O S Nielsen, J M Buesa, P C Lorigan, S Leyvraz, C Hermans, M van Glabbeke, J Verweij.
Abstract
Temozolomide, an oral imidazotetrazine derivative, was given to 31 patients with advanced soft tissue sarcoma. The dose of 750 mg/m2 was divided over 5 consecutive days, and escalated to 1000 mg/m2 over 5 days at cycle 2 if myelosuppression no worse than common toxicity criteria grade 2 was noted in the first 28-day cycle. A total of 99 treatment cycles were given to 31 patients. The drug was well tolerated, with nausea and vomiting as the most common side-effects. Only one partial tumour response was documented, giving a response rate of 3.33%, 95% confidence interval, (CI) 0.1-17.2%. The median time to progression was 8 weeks and the median survival was 27 weeks. These results indicate that temozolomide in this schedule is not active as second-line treatment in advanced soft tissue sarcoma.Entities:
Mesh：
Substances：
Year: 1999 PMID： 10448291 DOI： 10.1016/s0959-8049(98)00403-1
Source DB: PubMed Journal: Eur J Cancer ISSN： 0959-8049 Impact factor: 9.162